ArticleJournal of ophthalmology2026
A One-Year Visual and Safety Evaluation of a Newly Available Trifocal Intraocular Lens in Patients With Bilateral Cataracts: Clinical Outcomes From a Prospective Study.
Article in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the effectiveness and safety of a new trifocal intraocular lens (IOL) in patients with age-related cataracts 12 months after surgery. Methods: This prospective, noncomparative, multicenter study included 122 patients (244 eyes) undergoing cataract surgery with bilateral implantation of the AT ELANA 841P. At 12 months postoperatively, refraction and binocular visual acuity (VA) at distance (4 m), intermediate (80 cm), and near (40 cm) were measured. Visual symptoms and spectacle independence were subjectively evaluated. Safety assessment included the rate of ocular adverse events (AEs), posterior capsule opacification (PCO), IOL tilt and decentration, and glistening formation. Results: At 12 months postoperatively, most eyes (90.6%) were within ± 0.5 D spherical equivalent (SE) refraction, and almost all (99.6%) were within ± 1.0 D. Overall, 100% of patients achieved binocular uncorrected VA of 0.2 logMAR or better at distance. Performance at intermediate and near was 98.4% and 88.5%, respectively. All patients were spectacle-free at far and intermediate distances (100%), and 88.5% were spectacle-free for near tasks; over 80% reported no visual symptoms. The eye-related AE rate was low, with mild-to-moderate intensity. Up to 12 months, 91.7% of the eyes had no PCO, while 3.2% were treated with posterior capsulotomy. IOL tilt was not observed; only a small number of decentration cases were monitored, and these were clinically insignificant (< 1 mm) at the final visit. At 12 months, the IOL showed no glistening (97.5%) or traces only. Conclusion: Implantation of the AT ELANA 841P provided reliable refractive and visual outcomes, high rates of spectacle independence, and corrected and uncorrected VA at all distances. The IOL exhibited a favorable safety profile over 12 months, characterized by minimal visual symptoms, low PCO, no glistening (or only trace), and a stable position in the eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.